Aerobic training decreases bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: a randomised controlled trial

Andrezza França-Pinto,1 Felipe A R Mendes,2 Regina Maria de Carvalho-Pinto,3 Rosana Câmara Agondi,1 Alberto Cukier,2 Rafael Stelmach,3 Beatriz M Saraiva-Romanholo,4 Jorge Kalil,1 Milton A Martins,4 Pedro Giavina-Bianchi,1 Celso R F Carvalho2

ABSTRACT

Background The benefits of aerobic training for the main features of asthma, such as bronchial hyperresponsiveness (BHR) and inflammation, are poorly understood. We investigated the effects of aerobic training on BHR (primary outcome), serum inflammatory cytokines (secondary outcome), clinical control and asthma quality of life (Asthma Quality of Life Questionnaire (AQLQ)) (tertiary outcomes).

Methods Fifty-eight patients were randomly assigned to either the control group (CG) or the aerobic training group (TG). Patients in the CG (educational programme + breathing exercises (sham)) and the TG (same as the CG+aerobic training) were followed for 3 months. BHR, serum cytokine, clinical control, AQLQ, induced sputum and fractional exhaled nitric oxide (FeNO) were evaluated before and after the intervention.

Results After 12 weeks, 43 patients (21 CG/22 TG) completed the study and were analysed. The TG improved in BHR by 1 doubling dose (dd) (95% CI 0.3 to 1.7 dd), and they experienced reduced interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) (ACQ-7; p>0.05). A within-group difference was found to either the control group (CG) or the aerobic training group (TG). Patients in the CG (educational programme + breathing exercises (sham)) and the TG (same as the CG+aerobic training) were followed for 3 months. BHR, serum cytokine, clinical control, AQLQ, induced sputum and fractional exhaled nitric oxide (FeNO) were evaluated before and after the intervention.

Conclusions Aerobic training reduced BHR and serum proinflammatory cytokines and improved quality of life and asthma exacerbation in patients with moderate or severe asthma. These results suggest that adding exercise as an adjunct therapy to pharmacological treatment could improve the main features of asthma.

Trial registration number NCT02033122.

INTRODUCTION

Asthma, defined as a chronic inflammatory disorder of the airways, is characterised by airway obstruction and bronchial hyperresponsiveness (BHR) and is associated with recurrent episodes of wheezing, breathlessness, chest tightness and coughing. Asthma symptoms experienced during daily physical activities or the fear of triggering asthma may keep patients with asthma from engaging in physical exercise, which often leads to a detrimental health cycle and an aversion to exercise, and reduces activity in daily life and physical fitness. Interestingly, a low level of physical activity has been strongly and independently associated with increased BHR in patients with asthma.

However, exercise training has been proposed as an adjunctive therapy in asthma treatment because it improves physical fitness, health-related quality of life (HRQoL),6 and asthma symptoms, and because it reduces corticosteroid consumption. However, the effects of exercise training on BHR remain controversial. Two recent systematic reviews evaluated the effects of aerobic training on BHR and reported either no benefit9 or only a trend towards lower BHR after exercise training.10

What is the key question?

▸ Does aerobic exercise improve bronchial hyperresponsiveness and airway and systemic inflammation in patients with moderate or severe asthma?

What is the bottom line?

▸ Improvements in aerobic fitness reduced bronchial hyperresponsiveness in one doubling dose of histamine and reduced systemic inflammation in patients with moderate or severe asthma under optimal medical treatment, suggesting that this therapy is an important adjuvant in asthma treatment.

Why read on?

▸ This randomised and controlled trial provides the first evidence, obtained using a gold-standard method, that improvement in aerobic exercise reduces bronchial hyperresponsiveness and systemic inflammation.

Key messages

▸ Does aerobic exercise improve bronchial hyperresponsiveness and airway and systemic inflammation in patients with moderate or severe asthma?

▸ Improvements in aerobic fitness reduced bronchial hyperresponsiveness in one doubling dose of histamine and reduced systemic inflammation in patients with moderate or severe asthma under optimal medical treatment, suggesting that this therapy is an important adjuvant in asthma treatment.
The lack of evidence observed in these reviews is explained by the great diversity in patient disease severity, clinical control status and medication management. In addition, BHR in these studies was not properly evaluated using a doubling dose, which is the gold-standard method recommended by current guidelines and has been widely used in clinical trials. As a consequence, both meta-analyses recommended performing well-designed trials using standardised tools and more detailed sample characterisation to investigate the potential benefits of regular exercise on BHR in patients with asthma.

Although the effect of aerobic training on BHR in patients with asthma remains poorly understood, studies in asthma animal models have demonstrated that exercise training reduces airway responsiveness and inflammation. Three potential mechanisms have been proposed: reductions in expression of the T helper 2 (Th2) cytokines interleukin (IL)-4, IL-5 and IL-13, reductions in the chemokines monocyte chemo-attractant protein (MCP) and keratinocyte chemoattractant (KC; murine homologue to human IL-8) and increases in the anti-inflammatory cytokine IL-10. To the best of our knowledge, no previous study has investigated such mechanisms in patients with asthma. Given that BHR and inflammation are characteristic features of asthma and given that exercise has systemic anti-inflammatory effects, the aim of the present study was to investigate the effects of aerobic training on BHR (primary aim) and serum inflammatory cytokines (secondary aim). In addition, clinical control, asthma quality of life and airway inflammation were evaluated (tertiary outcomes).

METHODS
Detailed study methods are provided in the online supplementary appendix.

Subjects
Outpatients with moderate or severe persistent asthma, aged between 20 and 59 years, were recruited from a University Hospital. The Ethics Review Board of the Clinical Hospital approved the study (protocol 0121/10). All patients signed an informed consent form and the trial was registered at ClinicalTrials.gov (NCT02033122). Asthma was diagnosed according to the Global Initiative for Asthma, and disease severity was determined by combining the current level of symptoms, pulmonary function and maintenance treatment. The patients were managed under optimal medical treatment, monitored by pulmonologists for at least 6 months and considered clinically stable (without exacerbations or changes in medication for at least 30 days).

Patients who met the following criteria were excluded: cardiovascular, musculoskeletal or other chronic lung diseases; current treatment for at least 30 days). Bronchial hyperresponsiveness was evaluated using the methacholine challenge test. Each session lasted 30 min and was supervised by a physiotherapist. Breathing exercises were included as a sham intervention in the CG to prevent differences in the number of hospital visits and to reduce possible differences in the amount of attention between groups but not to induce benefits in patients with asthma.

Interventions
Breathing exercise programme
Both groups completed a yoga breathing exercise programme twice a week for 12 weeks. Each session lasted 30 min and was supervised by a physiotherapist. Breathing exercises were included as a sham intervention in the CG to prevent differences in the number of hospital visits and to reduce possible differences in the amount of attention between groups but not to induce benefits in patients with asthma.

Aerobic training programme
All subjects from the TG completed the aerobic training programme twice a week for 12 weeks on an indoor treadmill. Each aerobic training session lasted 35 min and was divided into 5 min of warm-up, 25 min of aerobic training and 5 min of cool-down. At the end of the programme, all the subjects were performing vigorous training, based on the anaerobic threshold (AnT) and the respiratory compensation point.

Assessments
Bronchial hyperresponsiveness
A bronchial provocation test with histamine was conducted according to American Thoracic Society (ATS) guidelines. The test was considered positive when the histamine concentration promoted a decrease ≥20% in forced expiratory volume in 1 s (FEV₁, PC20).

Serum cytokines and total IgE
The cytometric bead array method (BD Biosciences, San Jose, California, USA) was used to analyse the levels of IL-4, IL-5, IL-6, IL-10, tumour necrosis factor (TNF)-α, IL-12p70, IL-8/CXCL8, MCP-1/CCL2 and RANTES/CCL5. Total serum IgE was measured by nephelometry using commercially available kits (Dade Behring/Siemens, Deerfield, Illinois, USA).

Fractional exhaled nitric oxide
All measurements were determined by chemiluminescence (Sievers 280) in accordance with the ATS recommendations. FeNO values were considered elevated at ≥26 ppb.

Induced sputum
Sputum was collected and processed using a standard method. Eosinophil values were considered elevated at >3%.

Asthma symptoms and exacerbation
Asthma symptoms and exacerbation were evaluated using a daily diary of symptoms as previously reported. A day was considered free of asthma symptoms when the patient did not report any symptoms, and these days were totalled monthly. Asthma exacerbation was defined as an increase in symptoms associated with at least one of the following criteria: use of rescue medication ≥4 puffs per 24 h during a 48 h period, need for rescue medication at night, or ≥2 hospitalisations per year.
for systemic corticosteroids, unscheduled medical appointment, visit to an emergency room or hospitalisation.

Asthma control questionnaire
The ACQ-7 consists of seven questions related to asthma symptoms, use of short-acting β₂ agonists and FEV₁ in the percent of predicted values. The ACQ-6 is the same as the ACQ-7 without the question related to FEV₁.²⁴

Asthma quality of life
Asthma quality of life was assessed using the AQLQ,²⁵ which has four domains: activity limitations, symptoms, emotional function and environmental stimuli. A higher AQLQ score indicates a better quality of life.²⁵

Cardiopulmonary exercise test and pulmonary function
The test was performed on a treadmill with a ramp protocol, as recommended by the American College of Cardiology/American Heart Association.²⁶ Pulmonary function testing was performed according to the current ATS/European Respiratory Society guidelines.²⁷

Atopy
Patients were considered atopic if they presented a clinical history suggestive of respiratory allergy and specific IgE antibodies in the following tests: in vivo (skin prick test) and/or in vitro (Phadiatop test).

Statistical analysis
A sample size of 34 patients (17 in each group) was estimated to provide 80% power to detect a 1 doubling-dilution shift in histamine PC₂₀ value (minimal clinical difference), assuming a 1.0 within-patient SD in doubling-dilution shift and an α of 0.05 (two tailed).²⁸ PC₂₀ histamine changes were expressed in terms of doubling dose (dd) concentrations, calculated as Δ log PC₂₀/ log₂.²⁵ and Student’s t test was used to compare groups. ACQ, AQLQ, aerobic capacity and pulmonary function were summarised using means and SDs, and differences between the CG and TG were compared using Student’s unpaired t test. Sputum cell counting, FeNO, cytokine concentrations and total IgE were summarised using medians and IQRs (25% and 75%), and differences between the CG and TG were compared using the unpaired Mann–Whitney U test. The proportion of patients experiencing exacerbations between the TG and placebo CG were compared by

Figure 1  Flow of participants through the study (CONSORT diagram). CG, control group; TG, training group.
Table 1  Baseline characteristics of patients with asthma

<table>
<thead>
<tr>
<th>Anthropometric data</th>
<th>Control group (n=21)</th>
<th>Training group (n=22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (F/M)</td>
<td>17/4</td>
<td>17/5</td>
</tr>
<tr>
<td>Age, years old; mean (SD)</td>
<td>44 (9)</td>
<td>40 (11)</td>
</tr>
<tr>
<td>BMI, kg/m²; mean (SD)</td>
<td>26.4 (4.3)</td>
<td>26.5 (4.2)</td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budesonide dosage, μg/day; mean (SD)</td>
<td>804 (370)</td>
<td>909 (594)</td>
</tr>
<tr>
<td>Long-acting β₂ agonists, μg/day; mean (SD)</td>
<td>34.5 (32.1)</td>
<td>26.7 (17.7)</td>
</tr>
<tr>
<td>Onset of asthma in childhood, n (%)</td>
<td>12 (57)</td>
<td>17 (77)</td>
</tr>
<tr>
<td>IgE, IU/mL; median (25th–75th)</td>
<td>289.0 (57–877)</td>
<td>451.5 (151–1183)</td>
</tr>
<tr>
<td>Atey, n (%)</td>
<td>15 (71.4)</td>
<td>20 (91.0)</td>
</tr>
<tr>
<td>BHR, PC₂₀, mg/mL; median (25th–75th)</td>
<td>0.5 (0.3–1.7)</td>
<td>0.3 (0.2–0.5)</td>
</tr>
<tr>
<td>Eosinophilic, %; median (25th–75th)</td>
<td>6.1 (9)</td>
<td>10.1 (12)</td>
</tr>
<tr>
<td>FeNO, ppb; median (25th–75th)</td>
<td>26.7 (22.5–38.9)</td>
<td>32.0 (21.1–44.8)</td>
</tr>
<tr>
<td>ACQ-7, score; mean (SD)</td>
<td>1.6 (0.9)</td>
<td>1.4 (1.2)</td>
</tr>
<tr>
<td>Exacerbations in the last 12 months; no. events/patients</td>
<td>1.9</td>
<td>1.2</td>
</tr>
<tr>
<td>AQLQ, total score; mean (SD)</td>
<td>4.2 (1.1)</td>
<td>4.6 (1.4)</td>
</tr>
<tr>
<td>Aerobic capacity, VO₂max, mL/kg/min; mean (SD)</td>
<td>25.5 (5.9)</td>
<td>27.0 (4.3)</td>
</tr>
</tbody>
</table>

| Pulmonary function | FEV₁, %; mean (SD) | 66.3 (19.0)          | 69.0 (21.0)         |
|                    | FEV₁/FVC, %; mean (SD) | 72.2 (10.0)       | 73.0 (10.5)         |

Data are presented as mean±SD unless otherwise stated.

ACQ-7; Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BHR, bronchial hyperresponsiveness; BMI, body mass index; FeNO, fractional exhaled nitric oxide; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; IgE, immunoglobulin E; PC₂₀, provocation concentration of histamine causing a 20% decrease in FEV₁; ppb, parts per billion; VO₂max, maximal oxygen consumption.

RESULTS

A total of 464 subjects were assessed for eligibility: 303 were excluded, 103 refused to participate and 58 patients were randomised into two groups. Forty-three patients completed the study and were analysed (21 CG/22 TG) (figure 1). Both groups had similar baseline characteristics (table 1).

Bronchial hyperresponsiveness

Six patients (2 CG, 4 TG) were not able to perform the bronchial provocation test because they had FEV₁<1.0 L after medication was withdrawn for 12 h during the initial evaluation. At baseline, two patients were classified as borderline, five were classified as mildly hyperresponsive and 29 were classified as moderately to severely hyperresponsive. After the intervention, the BHR decreased in the TG (n=18), with an increment in PC₂₀ of 1 dd (95% CI 0.3 to 1.7 dd), and did not change in the CG (n=19) (0.06 dd; 95% CI –0.6 to 0.7 dd) (p=0.039; figure 2).

Cytokine and chemokine levels and total IgE

The CG and TG had similar baseline levels of cytokines (IL-5, IL-6, IL-8 and IL-10), but MCP-1 was higher in the TG (p=0.002) (table 2). There were significant reductions in IL-6 (p=0.042) and MCP-1 (p=0.045) in the TG compared with the CG (table 2). IL-8 was decreased in the TG, but the differences between groups were not significant (p=0.055). IL-5, IL-10 and IgE did not significantly change (p>0.05) (table 2). IL-4, TNF-α and RANTES were outside the limit of detection of the assay and could not be analysed.

Clinical asthma control

The number of days free of asthma symptoms increased in the TG after the intervention (p=0.042), with no difference between the groups (p=0.987, table 3). The frequency of exacerbations during treatment was lower in the TG compared with the CG (0.6 vs 1.5 exacerbations/patient; p=0.021). According to ACQ-7 before intervention, 12 patients were classified as having controlled asthma (<0.75), 12 partially controlled (0.75–1.5) and 19 uncontrolled (>1.5). TG patients with non-well-controlled asthma (ACQ-6>0.75 points, n=14) presented an improvement after aerobic training (p=0.001), with no differences between the groups (p=0.248, figure 3D). The same analysis using the ACQ-7 demonstrated no difference within or between the groups (p=0.785) (figure 3C).

Asthma quality of life questionnaire

Between-group differences were observed in the activity limitation (p=0.009) domains and in the AQLQ total score (p=0.034) in favour of the TG (table 3). Significant within-group improvement in the emotional function domain was seen in the TG (p=0.005), with no difference between the groups (p=0.084, table 3). Fifteen patients (68%) from the TG showed a clinically significant improvement in AQLQ total score (≥0.5 points). The TG presented a linear relationship between improvements in the ACQ-7 and AQLQ (r=−0.74, p<0.001).

Induced sputum cellularity and FeNO

The intervention did not induce a significant change in either sputum cellularity (p=0.648) or FeNO in either group (p=0.397) (table 3). Patients from the TG with increased eosinophilic inflammation (>3%, n=13) or FeNO (>26.0 ppb, n=12) at baseline presented a significant reduction in these values (p=0.015 and 0.019, respectively), but the differences between the groups were not significant (p=0.533 and 0.452, respectively; figures 3A, B). Eight patients in the CG and 9 in the TG presented increased eosinophilic inflammation and FeNO. The TG presented a linear relationship between baseline eosinophil counts and reduction after exercise training (in delta,

2 × 2 contingency tables using the χ² test. Within-group differences were compared by the paired t test. The level of significance was set at 5% (p<0.05) for all the tests. The statistical analysis was blinded to the treatment allocation and was performed using statistical software (SigmaStat 3.5, Systat Software Inc).
Table 2 Within-group comparison and between-group comparison for cytokine levels and total IgE in patients with asthma

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Control group (n=21)</th>
<th>Training group (n=22)</th>
<th>Treatment effect</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before (n=21)</td>
<td>Mean (95% CI) p Value</td>
<td>Before (n=22)</td>
</tr>
<tr>
<td>IL-5 (fg/mL)</td>
<td>129.2 (80.1 to 205.3)</td>
<td>46.8 (−3.3 to 95.6)</td>
<td>0.066</td>
</tr>
<tr>
<td>IL-6 (fg/mL)</td>
<td>298.2 (162.8 to 633.9)</td>
<td>67.6 (−186.7 to 220.0)</td>
<td>0.585</td>
</tr>
<tr>
<td>IL-8 (fg/mL)</td>
<td>1713.9 (1392 to 1858)</td>
<td>51.7 (−185.9 to 289.6)</td>
<td>0.655</td>
</tr>
<tr>
<td>IL-10 (fg/mL)</td>
<td>100.7 (1.0 to 166.7)</td>
<td>21.3 (−16.4 to 58.9)</td>
<td>0.253</td>
</tr>
<tr>
<td>MCP-1 (pg/mL)</td>
<td>14.1 (4.5 to 19.3)</td>
<td>0.5 (−2.8 to 3.9)</td>
<td>0.743</td>
</tr>
<tr>
<td>IgE (IU/mL)</td>
<td>289.0 (60.5 to 878.5)</td>
<td>65.4 (−133.3 to 264.1)</td>
<td>0.160</td>
</tr>
</tbody>
</table>

Values are presented as medians and (25th−75th percentiles). fg, femtogram; IgE, immunoglobulin E; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; pg, picogram.

DISCUSSION

The results of the current study demonstrate that a 12-week aerobic training programme reduces BHR and serum proinflammatory cytokines and improves quality of life and asthma exacerbation in adults with moderate to severe persistent asthma. In addition, it seems that aerobic training reduces sputum eosinophils and FeNO in patients with higher inflammation and improves clinical control in patients with worse asthma control. We are aware of only two randomised controlled trials that evaluated the effect of exercise training on BHR in adults with asthma, and their results are controversial.29,30 Arandelovic et al28 reported a significant improvement in histamine PC20 after 6 months of swimming training in patients with mild asthma who were treated with low doses of medication and had normal baseline pulmonary function. In contrast, Cochrane and Clark10 reported no change in histamine PC20 after 3 months of land aerobic training in patients with mild or moderate asthma using a higher dose of medication and with worse baseline pulmonary function. The discrepancy between these studies may have been multifactorial and depends on patient characteristics (disease severity, atopy, pharmacotherapy, exercise training programme (duration and intensity), and methodology of BHR analysis. The current study introduces several aspects that merit consideration and certainly add information to explain the effect of aerobic training on asthma pathophysiology for several reasons: this is the first study to observe a clinically significant increase of one doubling concentration in BHR, the proper methodology according the guideline;11 the benefit to BHR observed in our study may be explained only by the aerobic training because our patients were under proper medical treatment, in accordance with the recommended guidelines;3 we have studied patients with moderate to severe asthma, who often have a greater degree of BHR;11 and finally, in our study the patients’ clinical characteristics were thoroughly assessed, and the training programme was carefully monitored. These data strongly suggest that the observed effect in the BHR was relevant and was a direct result of the aerobic training.

By definition, BHR in asthma is associated with ongoing airway inflammation, and experimental studies in asthma animal models from our group and other groups have systematically shown that exercise reduces airway inflammation and remodelling.13–16 These effects seem to occur due to decreases in Th2 cytokines (IL-4, IL-5 and IL-13)13–16 and chemokines (MCP-1 and IL-8),15,16 and increases in the expression of the anti-inflammatory cytokine IL-10.11 In the present study, we investigated these mechanisms and observed that aerobic training reduced serum proinflammatory mediators IL-6 and MCP-1; unlike the results in asthma animal models, we did not observe any effect on IL-5, IL-10 and IL-8. Although it is not possible to establish a direct association among the reduction of BHR and IL-6, and MCP-1 observed in our study, there is enough evidence in the literature demonstrating the importance of these cytokines in airway inflammation and BHR in asthma.32 Additionally, we observed a within-group reduction in sputum eosinophil and FeNO in patients in the TG with worse airway inflammation, and that improvement was correlated with the baseline values, in agreement with previous findings from our group. This suggests that the benefits of aerobic training were associated with baseline airway inflammation.7 Interestingly, a recent study also observed a reduction in serum IL-6 and sputum eosinophils and neutrophils in obese patients with asthma submitted to exercise training and dietary changes. Taken together, these results indicate that exercise may have an anti-inflammatory effect in distinct asthma phenotypes.33

We also observed that aerobic training improved clinical control by reducing exacerbations in TG compared with CG. However, the ACQ-7 was not different between groups. Turner et al34 and Dogra et al also observed that aerobic training does not modify clinical control as evaluated by the ACQ-7; however, Dogra et al35 observed an improvement in patients with partially controlled asthma using the ACQ-6 (ACQ-7 without the FEV1 question). Similarly, significant within-group improvements in ACQ-6 were found in patients with non-well-controlled asthma from the TG, demonstrating that the improvement in the ACQ with aerobic training seems to be better quantified by using the ACQ-6 rather than the ACQ-7. These results may be explained by the widely known fact that aerobic training does not improve lung function.5 We also showed an average improvement in AQLQ score of 0.8 in the TG that is similar to the improvement observed by Turner et al34 (0.3) and Dogra et al35 (1.0), thereby confirming the importance of regular exercise to improve health-related quality of life, even in patients with asthma undergoing clinical treatment.

Certain limitations need to be addressed when interpreting our results. We evaluated the serum cytokine levels, which may not necessarily reflect airway inflammation; however, it has been extensively demonstrated that the effects of exercise training are more pronounced in the systemic immune response.5 In addition, the strict inclusion criteria used in our study limit the external validity of our findings; however, this was an important feature of the

Δ final–initial (r=−0.51; p=0.012). Similar results were observed in FeNO levels (r=−0.61; p=0.008).

Maximal aerobic capacity and pulmonary function

TG patients experienced increased maximal oxygen consumption (VO2max) (p=0.019) and aerobic power (p=0.029) compared with CG patients (table 3 and see online supplementary appendix table S1). No changes in spirometry were observed in either group (p>0.05) (table 3 and see online supplementary appendix table S2).
<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Control group (n=21)</th>
<th></th>
<th>Training group (n=22)</th>
<th></th>
<th>Treatment effect</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>Mean (95% CI)</td>
<td>p Value time</td>
<td>Before</td>
<td>Mean (95% CI)</td>
<td>p Value time</td>
</tr>
<tr>
<td></td>
<td></td>
<td>within-group difference</td>
<td></td>
<td></td>
<td>within-group difference</td>
<td></td>
</tr>
<tr>
<td>Clinical Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma symptom-free days</td>
<td>15.3 (11.0)</td>
<td>−2.5 (6.2 to 1.2)</td>
<td>0.180</td>
<td>12.0 (11.2)</td>
<td>−4.3 (−8.4 to −0.2)</td>
<td>0.042</td>
</tr>
<tr>
<td>ACQ-7</td>
<td>1.6 (0.9)</td>
<td>0.1 (−2.1 to 0.5)</td>
<td>0.395</td>
<td>1.4 (1.2)</td>
<td>0.2 (−0.2 to 0.5)</td>
<td>0.267</td>
</tr>
<tr>
<td>ACQ-6</td>
<td>1.5 (1.0)</td>
<td>0.1 (−2.8 to 0.6)</td>
<td>0.502</td>
<td>1.2 (1.2)</td>
<td>0.2 (−0.2 to 0.6)</td>
<td>0.236</td>
</tr>
<tr>
<td>AQLQ Overall</td>
<td>4.2 (1.1)</td>
<td>−0.3 (−0.8 to 0.2)</td>
<td>0.259</td>
<td>4.6 (1.4)</td>
<td>−0.7 (−1.9 to 0.2)</td>
<td>0.005</td>
</tr>
<tr>
<td>Activity limitation domain</td>
<td>3.8 (0.9)</td>
<td>−0.2 (−0.8 to 0.4)</td>
<td>0.435</td>
<td>4.3 (1.3)</td>
<td>−0.8 (−1.2 to −0.3)</td>
<td>0.002</td>
</tr>
<tr>
<td>Symptoms domain</td>
<td>4.8 (1.5)</td>
<td>−0.2 (−0.9 to 0.4)</td>
<td>0.469</td>
<td>5.1 (1.5)</td>
<td>−0.6 (−1.1 to 0.0)</td>
<td>0.053</td>
</tr>
<tr>
<td>Emotional function domain</td>
<td>4.1 (1.9)</td>
<td>−0.6 (−1.6 to 0.4)</td>
<td>0.250</td>
<td>4.6 (1.8)</td>
<td>−1.0 (−1.6 to −0.3)</td>
<td>0.005</td>
</tr>
<tr>
<td>Environmental stimuli domain</td>
<td>3.7 (1.8)</td>
<td>−0.5 (−1.5 to 0.6)</td>
<td>0.359</td>
<td>4.5 (2.0)</td>
<td>−0.6 (−1.3 to 0.2)</td>
<td>0.118</td>
</tr>
<tr>
<td>Induced sputum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cell (10⁶/mL) median (25th–75th)</td>
<td>0.9 (0.1–1.4)</td>
<td>−0.8 (−1.5 to 0.2)</td>
<td>0.055</td>
<td>0.8 (0.4 to 1.6)</td>
<td>0.2 (−0.44 to 0.77)</td>
<td>0.583</td>
</tr>
<tr>
<td>Eosinophils (%) median (25th–75th)</td>
<td>6.1 (0.25–14.9)</td>
<td>−7.9 (−17.7 to 1.8)</td>
<td>0.106</td>
<td>10.1 (1.6 to 21.9)</td>
<td>−0.6 (−8.8 to 7.6)</td>
<td>0.881</td>
</tr>
<tr>
<td>Neutrophils (%) median (25th–75th)</td>
<td>33.8 (22.1–66.2)</td>
<td>−3.4 (−6.9 to 13.7)</td>
<td>0.500</td>
<td>37.4 (16.7 to 57.5)</td>
<td>−1.6 (−12.6 to 15.7)</td>
<td>0.821</td>
</tr>
<tr>
<td>Lymphocytes (%) median (25th–75th)</td>
<td>0.0 (0.0–0.1)</td>
<td>0.9 (−2.7 to 4.4)</td>
<td>0.620</td>
<td>0.0 (0.0 to 0.8)</td>
<td>−1.2 (−2.9 to 0.4)</td>
<td>0.137</td>
</tr>
<tr>
<td>Macrophages (%) median (25th–75th)</td>
<td>40.5 (11.1–73.1)</td>
<td>1.4 (−9.8 to 12.5)</td>
<td>0.799</td>
<td>43.4 (25.7 to 65.2)</td>
<td>−0.9 (−16.1 to 14.4)</td>
<td>0.907</td>
</tr>
<tr>
<td>FeNO (ppb) median (25th–75th)</td>
<td>26.7 (22.5–38.9)</td>
<td>−5.9 (−5.8 to 4.6)</td>
<td>0.815</td>
<td>32.0 (21.1 to 44.8)</td>
<td>4.5 (−0.7 to 9.7)</td>
<td>0.087</td>
</tr>
<tr>
<td>Exercise capacity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aerobic capacity (VO₂max mL/kg/min)</td>
<td>25.5 (5.9)</td>
<td>2.4 (−0.2 to 4.5)</td>
<td>0.053</td>
<td>27.0 (4.2)</td>
<td>−1.0 (−2.4 to 0.5)</td>
<td>0.182</td>
</tr>
<tr>
<td>Maximal workload (watts)</td>
<td>202.8 (67.3)</td>
<td>−3.3 (−25.4 to 18.9)</td>
<td>0.762</td>
<td>190.3 (32.3)</td>
<td>−57.1 (−73.1 to −41.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pulmonary function</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV₁ (L)</td>
<td>2.00 (0.7)</td>
<td>−0.1 (−0.2 to 0.1)</td>
<td>0.471</td>
<td>2.1 (0.76)</td>
<td>0.00 (−0.1 to 0.1)</td>
<td>0.952</td>
</tr>
<tr>
<td>FEV₁ % predicted</td>
<td>66.3 (19.0)</td>
<td>−2.3 (−8.6 to 3.9)</td>
<td>0.447</td>
<td>69.0 (21.0)</td>
<td>−1.1 (−4.8 to 2.6)</td>
<td>0.546</td>
</tr>
</tbody>
</table>

Data are means (SDs) unless otherwise stated.

ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; FeNO, fractional exhaled nitric oxide.
study design to reduce variability within the sample for the main outcome (BHR). Finally, for subgroup analysis, significant between-group differences following treatment could not be demonstrated, probably due to the reduced number of individuals, because the sample size was not primarily to evaluate these secondary outcomes. Although, it well known that the key outcome in a clinical trial is the difference between the intervention and CGs, if the sample size is not primarily to evaluate these secondary outcomes. As a consequence, this information should subsidise future studies aiming to evaluate differences between treatments to determine the impact of exercise on clinical control and airway inflammation.

In conclusion, our results demonstrate that aerobic training reduces BHR, systemic inflammation and exacerbations and improved quality of life in adults with moderate to severe persistent asthma. In addition, we showed that patients with higher inflammation and lower asthma control obtained greater benefits. These findings suggest that adding exercise as an adjunct therapy to pharmacotherapy can improve the main features of asthma pathophysiology.

Acknowledgements The authors would like to acknowledge: Dr Júlia M D Greve and the exercise physiologist Paulo R Santos-Silva (Institute of Orthopedics and Traumatology, Clinics Hospital, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil) for their support and blinded analysis of the cardiopulmonary exercise testing; Professor Maria N Sato and PhD student Luanda M S Oliveira (Laboratory of Dermatology and Immunodeficiencies, Department of Dermatology, Medical School, University of Sao Paulo, Sao Paulo, Brazil) for conducting the blood sample analysis; and Professor Clarice Tanaka (Department of Physical Therapy, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil) for her technical support. The authors would also like to acknowledge the American Thoracic Society (ATS) and the Methods in Epidemiologic, Clinical and Operations Research (MECOR) Program for their assistance in the development of research skills in Latin America.

Contributors AF-P: study concept and design, recruitment of patients, manuscript writing and review, data acquisition and results interpretation; FARM (principal contributor guarantor): study concept and design, recruitment of patients, manuscript writing and review, data acquisition; results interpretation and statistical analysis; RMdC-P: patient’s medical treatment and manuscript review; RCA: bronchial provocation test support, blinded outcome assessment and manuscript review; AC and RS: study concept and design, results interpretation and manuscript review; BMS-R: blinded outcome assessment, cytospin reading, FeNO analysis, and manuscript review; JK: project supervision and manuscript review; MAM: project supervision, study concept and design, and manuscript review; PG-B: project supervision, study concept and design, manuscript review and results interpretation; CRFC: study concept and design, project supervision, results interpretation, overall study coordination, and manuscript writing and review. All the authors have read and approved the final version of the manuscript.

Funding The study was supported by the São Paulo Research Foundation (FAPESP; Grants 2009/53904-9 and 2009/53817-9) and Ministério da Ciência, Tecnologia e Inovação—Conselho Nacional de Pesquisa (CNPq Grants 305987/2010-0).

Competing interests None declared.

Ethics approval Clinical Hospital (protocol 0121/10).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
Exercise is associated with improved asthma control in adults. 

Respiratory research

Aerobic training decreases bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: a randomised controlled trial

Andrezza França-Pinto, Felipe A R Mendes, Regina Maria de Carvalho-Pinto, Rosana Câmara Agondi, Alberto Cukier, Rafael Stelmach, Beatriz M Saraiva-Romanholo, Jorge Kalil, Milton A Martins, Pedro Giavina-Bianchi and Celso R F Carvalho

Thorax 2015 70: 732-739 originally published online June 10, 2015
doi: 10.1136/thoraxjnl-2014-206070

Updated information and services can be found at:
http://thorax.bmj.com/content/70/8/732

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2015/05/07/thoraxjnl-2014-206070.DC1
http://thorax.bmj.com/content/suppl/2015/06/10/thoraxjnl-2014-206070.DC2
http://thorax.bmj.com/content/suppl/2015/05/07/thoraxjnl-2014-206070.DC3

References
This article cites 33 articles, 6 of which you can access for free at:
http://thorax.bmj.com/content/70/8/732#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Editor's choice (125)
Press releases (31)
Asthma (1782)
Inflammation (1020)
Clinical trials (epidemiology) (557)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/